On January 12, 2018, Arbutus Biopharma Corporation closed the transaction. The company received its second tranche. As a part of transaction, investor has right to nominate certain number of directors.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11.44 USD | -1.51% |
|
+2.31% | +2.49% |
07-10 | Piper Sandler Adjusts Price Target on Roivant Sciences to $22 From $20, Maintains Overweight Rating | MT |
07-01 | Roivant Sciences Ltd.(NasdaqGS:ROIV) added to Russell 1000 Defensive Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.49% | 8.58B | |
+56.88% | 848B | |
+33.13% | 627B | |
-0.31% | 363B | |
+16.08% | 318B | |
+12.65% | 299B | |
+15.17% | 243B | |
+17.11% | 225B | |
+16.28% | 179B | |
+4.91% | 167B |
- Stock Market
- Equities
- ROIV Stock
- News Roivant Sciences Ltd.
- Arbutus Biopharma Corporation announced that it has received CAD 116.4 million in funding from Roivant Sciences Ltd.